EnnoDC I About
EnnoDC I Overview
EnnoDC is a clinical-stage biotech that designs and develops DC engagers.
By simultaneously allowing antigen-priming and controlled activation of dendritic cells in-vivo, these next generation immunotherapies induce a precise, broad and durable immune response in patients with the toughest cancer or viral infection.
Our proprietary DC engagers’ studio has fueled a dynamic pipeline of 5 antibody candidates. After a first clinical validation in HIV and COVID-19, the company is now advancing two programs in HPV16+ oropharyngeal and prostate cancer.
Founded in 2020, the company is located in PariSanté Campus (Paris, France) and Kendall Square (Cambridge, Massachusetts, USA).
EnnoDC I Team
We are led by a seasoned management team and supported by internationally recognized leaders in biomedicine, industry and business.
Management Team
Supervisory Board
Scientific Advisory Committees
EnnoDC I Partners
EnnoDC is a spin-off of the Vaccine Research Institute (VRI) and INSERM led by top-tier immunologists and supported by world-leading researchers and clinicians.
The company has a long-standing partnership with the Baylor Institute for Immunology Research (Dallas, Texas) and conducts strategic collaborations with world’s top institutes and bioclusters in oncology including Moffitt Cancer Centre in the USA and Gustave Roussy Cancer Campus and Paris Saclay Cancer Cluster in France.
EnnoDC I Contact
If you wish to contribute, collaborate or learn more about EnnoDC’s advances, we would be delighted to hear from you.
Contact
